Moreover, ErbB2 downregulates Irf6, a member of the interferon-regulatory factor family of transcription factors, in HER2-positive BC cells to block anoikis and promote anchorage-independent growth by activating MAP kinases that inhibit transcription factor ∆Np63α-dependent signals required for Irf6 upregulation [153]. The gene discussed is ERBB2; the disease is breast cancer.